Squarepoint
DSGN icon

Squarepoint’s Design Therapeutics DSGN Stock Holding History

Squarepoint’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$429K Sell
29,630
-56,487
-66% -$704K ﹤0.01% 3539
2026
Q1 		$916K Buy
86,117
+39,975
+87% +$404K ﹤0.01% 2840
2025
Q4 		$433K Buy
+46,142
New +$361K ﹤0.01% 3325
2025
Q1 		– Sell
-48,186
Closed -$297K – 4770
2024
Q4 		$297K Sell
48,186
-36,945
-43% -$214K ﹤0.01% 4151
2024
Q3 		$458K Sell
85,131
-4,824
-5% -$22.7K ﹤0.01% 3167
2024
Q2 		$301K Buy
89,955
+53,518
+147% +$209K ﹤0.01% 3429
2024
Q1 		$147K Sell
36,437
-1,992
-5% -$5.32K ﹤0.01% 3711
2023
Q4 		$102K Sell
38,429
-4,133
-10% -$9.47K ﹤0.01% 3753
2023
Q3 		$100K Buy
42,562
+972
+2% +$4.53K ﹤0.01% 3556
2023
Q2 		$262K Sell
41,590
-67,624
-62% -$414K ﹤0.01% 3050
2023
Q1 		$630K Buy
+109,214
New +$817K ﹤0.01% 2168
2021
Q2 		– Sell
-23,493
Closed -$702K – 3342
2021
Q1 		$702K Buy
+23,493
New +$792K ﹤0.01% 1776

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Squarepoint's DSGN Position: Q2 2026 in Review

Squarepoint reduced its Design Therapeutics (DSGN) stake by 66% in Q2 2026, selling an estimated $704K and leaving 29,630 shares worth $429K. The position accounts for ﹤0.01% of the portfolio, ranked #3539.

Squarepoint first reported a position in DSGN in Q1 2021 and has held it in 12 quarters since. The position peaked at $916K in Q1 2026. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Squarepoint held 29,630 shares of Design Therapeutics worth $429K as of Q2 2026.
  • Squarepoint sold 56,487 Design Therapeutics shares in Q2 2026, an estimated $704K.
  • Design Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3539 holding.
  • Squarepoint first reported a position in Design Therapeutics in Q1 2021 and has held it in 12 quarters since.
  • Squarepoint's Design Therapeutics position peaked at $916K in Q1 2026.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.